Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Eisai Begins Marketing Diabetes II Drug in China

publication date: Sep 8, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Eisai Pharma announced it has begun China marketing of Glufast®, a phenylalanine derived rapid-acting insulin secretagogue that stimulates insulin production. In 2007, Eisai in-licensed rights to sell Glufast in 10 ASEAN countries from Kissei Pharmaceutical Co., which discovered and developed the drug. It was approved by the SFDA in November 2009. More details....

Stock Symbol: (TSE: 4523)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners